Johan W. Mouton

1990–2023 年に発表

121
論文数
19,674
被引用数
82
h 指数
121
i10 指数

被引用数

Johan W. Mouton の年別被引用数1965 年: 被引用 1 件1992 年: 被引用 1 件1994 年: 被引用 3 件1995 年: 被引用 7 件1996 年: 被引用 15 件1997 年: 被引用 12 件1998 年: 被引用 23 件1999 年: 被引用 30 件2000 年: 被引用 28 件2001 年: 被引用 28 件2002 年: 被引用 43 件2003 年: 被引用 42 件2004 年: 被引用 57 件2005 年: 被引用 65 件2006 年: 被引用 62 件2007 年: 被引用 81 件2008 年: 被引用 69 件2009 年: 被引用 79 件2010 年: 被引用 64 件2011 年: 被引用 100 件2012 年: 被引用 103 件2013 年: 被引用 88 件2014 年: 被引用 122 件2015 年: 被引用 136 件2016 年: 被引用 147 件2017 年: 被引用 145 件2018 年: 被引用 178 件2019 年: 被引用 750 件2020 年: 被引用 718 件2021 年: 被引用 642 件2022 年: 被引用 632 件2023 年: 被引用 474 件2024 年: 被引用 720 件2025 年: 被引用 318 件2026 年: 被引用 8 件1966〜1991 年は被引用が無いため表示していません1993 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,438 件、この内訳の 16.6%中国: 引用元論文 543 件、この内訳の 6.3%イギリス: 引用元論文 542 件、この内訳の 6.3%オランダ: 引用元論文 521 件、この内訳の 6%オーストラリア: 引用元論文 476 件、この内訳の 5.5%フランス: 引用元論文 438 件、この内訳の 5%イタリア: 引用元論文 424 件、この内訳の 4.9%ドイツ: 引用元論文 354 件、この内訳の 4.1%スペイン: 引用元論文 340 件、この内訳の 3.9%スイス: 引用元論文 233 件、この内訳の 2.7%カナダ: 引用元論文 230 件、この内訳の 2.6%スウェーデン: 引用元論文 217 件、この内訳の 2.5%
0%16.6%その他 33.6%

分野

  • Medicine52.2%
  • Biochemistry, Genetics and Molecular Biology29.4%
  • Immunology and Microbiology9%
  • Agricultural and Biological Sciences2.1%
  • Environmental Science1.8%
  • Pharmacology, Toxicology and Pharmaceutics1.4%
  • その他4.1%

トピック

  • Antibiotic Resistance in Bacteria13.1%
  • Antibiotics Pharmacokinetics and Efficacy11.8%
  • Antibiotic Use and Resistance5.8%
  • Antifungal resistance and susceptibility4.7%
  • Bacterial Identification and Susceptibility Testing3.1%
  • Fungal Infections and Studies3.1%
  • その他58.4%

共著者

全論文

検索で開く
  1. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

    著者: , , , , , , , , , , , , , , , , , , , , - Clinical Microbiology and Infection 2021 被引用: 995

  2. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

    著者: , , , , , , , , , , , , , , , , , - Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy 2019 被引用: 931

  3. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Infectious Diseases 2018 被引用: 624

  4. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

    著者: , , , , , , , , , , , , , - The Lancet Infectious Diseases 2014 被引用: 1,018

  5. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis

    著者: , , , , , , , , , , , , - The Lancet Infectious Diseases 2016 被引用: 746

  6. Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications and usage

    著者: , , , , , , - Clinical Microbiology and Infection 2019 被引用: 254

  7. Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management

    著者: , , , , - Journal of Fungi 2019 被引用: 291

  8. EUCAST expert rules in antimicrobial susceptibility testing

    著者: , , , , , , , , , , , , , - Clinical Microbiology and Infection 2011 被引用: 684

  9. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

    著者: , , , , , , , , , , , - The Lancet Infectious Diseases 2014 被引用: 343

  10. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nizar Andria, Ami Neuberger, Anat Stern, Neta Petersiel, Marina Raines, Amir Karban, Leonard Leibovici, Dafna Yahav, Noa Eliakim‐Raz, Oren Zusman, Michal Elbaz, Heyam Atamna, Vered Daitch, Tanya Babich, Yehuda Carmeli, Amir Nutman, Amos Adler, Inbar Levi, George L. Daikos, Anna Skiada, Ioannis Pavleas, Anastasia Antoniadou, Antigoni Kotsaki, Emanuele Durante‐Mangoni, Roberto Andini, Domenico Iossa, Mariano Bernardo, Giusi Cavezza, Lorenzo Bertolino, Giuseppe Giuffrè, Roberto Giurazza, Susanna Cuccurullo, Maria Galdo, Patrizia Murino, Adriano Cristinziano, Antonio Corcione, Rosa Zampino, Pia Clara Pafundi - Clinical Infectious Diseases 2018 被引用: 126

  11. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria

    著者: , , , - Drug Resistance Updates 2012 被引用: 344

  12. MIC-based dose adjustment: facts and fables

    著者: , , , , , - Journal of Antimicrobial Chemotherapy 2017 被引用: 327

  13. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing

    著者: , , , , , , , , , , - Clinical Microbiology and Infection 2006 被引用: 326

  14. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women

    著者: , , , , , , , , , , , , , , , , - JAMA 2018 被引用: 213

  15. Fosfomycin: Pharmacological, Clinical and Future Perspectives

    著者: , , , , , , , , - Antibiotics 2017 被引用: 196

  16. Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development

    著者: , , , , - Seminars in Respiratory and Critical Care Medicine 2015 被引用: 193

  17. Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates – the EUCAST broth microdilution reference method for MIC determination

    著者: , , , , , , , , , , , , , - Clinical Microbiology and Infection 2020 被引用: 107

  18. Protein Binding: Do We Ever Learn?

    著者: , , , , , , - Antimicrobial Agents and Chemotherapy 2011 被引用: 247

  19. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach

    著者: , , , , , , , , , , - Clinical Microbiology and Infection 2011 被引用: 280

  20. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials

    著者: , , , , , - Journal of Antimicrobial Chemotherapy 2015 被引用: 258

  21. Aspergillusand aspergilloses in wild and domestic animals: a global health concern with parallels to human disease

    著者: , , , , , , - Medical Mycology 2015 被引用: 226

  22. Use of a Novel Panel of Nine Short Tandem Repeats for Exact and High-Resolution Fingerprinting of Aspergillus fumigatus Isolates

    著者: , , , , , - Journal of Clinical Microbiology 2005 被引用: 251

  23. Time-kill kinetics of antibiotics active against rapidly growing mycobacteria

    著者: , , , , - Journal of Antimicrobial Chemotherapy 2014 被引用: 99

  24. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Neta Petersiel, Marina Raines, Amir Karban, Leonard Leibovici, Dafna Yahav, Noa Eliakim‐Raz, Oren Zusman, Michal Elbaz, Heyam Atamna, Vered Daitch, Tanya Babich, Yehuda Carmeli, Amir Nutman, Amos Adler, Inbar Levi, George L. Daikos, Anna Skiada, Ioannis Pavleas, Anastasia Antoniadou, Antigoni Kotsaki, Emanuele Durante‐Mangoni, Roberto Andini, Domenico Iossa, Mariano Bernardo, Giusi Cavezza, Lorenzo Bertolino, Giuseppe Giuffrè, Roberto Giurazza, Susanna Cuccurullo, Maria Galdo, Patrizia Murino, Adriano Cristinziano, Antonio Corcione, Rosa Zampino, Pia Clara Pafundi, Johan W. Mouton, Lena E. Friberg, Anders Kristoffersson, Ursula Theuretzbacher - Clinical Microbiology and Infection 2020 被引用: 78